SHC
Sotera Health Co
Sotera Health Co historical holders
total: 1
Greenlight Capital Sotera Health Co transactions over time
- Total transactions:
- 8
- New positions:
- 2
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 2
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
David Einhorn has been an institutional investor in Sotera Health Co (SHC) since 2023 Q2. According to 2026 Q1 report, David Einhorn holds 2,065,680 shares with a market value of roughly $29.62M representing 0.93% of their equity portfolio. The fund/company first acquired SHC in 2023 Q2, initially purchasing 5,450 shares. David Einhorn later completely sold out the position and reinvested in SHC again in 2025 Q2. Since the initial investment, Greenlight Capital has made 7 more transactions in this position.
Does David Einhorn still hold SHC?
Yes, David Einhorn continues to hold Sotera Health Co (SHC). According to their 2026 Q1 report, they maintain a position of 2,065,680 shares valued at approximately $29.62M, representing 0.93% of their equity portfolio.
When did David Einhorn first invest in SHC?
David Einhorn first invested in Sotera Health Co (SHC) in 2023 Q2 at the reported quarter-end price of $18.84 per share, acquiring 5,450 shares in their initial purchase.
What is David Einhorn's average cost basis for SHC?
Based on historical transaction data, David Einhorn's estimated cost basis for Sotera Health Co (SHC) is approximately $14.42 per share. This represents their average reported price* across all buy transactions.
Has David Einhorn reinvested in SHC after selling?
Yes, David Einhorn has shown renewed interest in Sotera Health Co (SHC). After completely selling their position, they reinitiated an investment in 2025 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $14.42
- Weighted AVG sell price:
- $15.73
SHC transactions history by Greenlight Capital
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.93%
|
2,065,680
|
$14.34
|
$29,621,851
|
+347.82% (+1,604,410)
|
+0.72%
|
|
2025 Q4
|
0.29%
|
461,270
|
$17.64
|
$8,136,803
|
+155.44% (+280,690)
|
+0.17%
|
|
2025 Q3
|
0.11%
|
180,580
|
$15.73
|
$2,840,524
|
-22.73% (-53,110)
|
-0.04%
|
|
2025 Q2
|
0.11%
|
233,690
|
$11.12
|
$2,598,632
|
new
|
+0.11%
|
|
2024 Q3
|
0.00%
|
0
|
$11.87
|
|
-100% (-300,110)
|
-0.17%
|
|
2024 Q1
|
0.16%
|
300,110
|
$12.01
|
$3,604,321
|
-10.94% (-36,860)
|
-0.02%
|
|
2023 Q3
|
0.29%
|
336,970
|
$14.98
|
$5,047,810
|
+6,082.94% (+331,520)
|
+0.28%
|
|
2023 Q2
|
0.00%
|
5,450
|
$18.84
|
$102,678
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.